Femasys (FEMY) Competitors $0.92 +0.08 (+8.84%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. FONR, MGRM, NSPR, SRTS, INO, MLSS, VANI, CTCX, EDAP, and HYPRShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include FONAR (FONR), Monogram Orthopaedics (MGRM), InspireMD (NSPR), Sensus Healthcare (SRTS), Inovio Pharmaceuticals (INO), Milestone Scientific (MLSS), Vivani Medical (VANI), Carmell (CTCX), Edap Tms (EDAP), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors FONAR Monogram Orthopaedics InspireMD Sensus Healthcare Inovio Pharmaceuticals Milestone Scientific Vivani Medical Carmell Edap Tms Hyperfine Femasys (NASDAQ:FEMY) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership. Do institutionals & insiders hold more shares of FEMY or FONR? 65.3% of Femasys shares are owned by institutional investors. Comparatively, 50.6% of FONAR shares are owned by institutional investors. 11.5% of Femasys shares are owned by insiders. Comparatively, 1.6% of FONAR shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, FEMY or FONR? Femasys has a beta of -2.62, indicating that its share price is 362% less volatile than the S&P 500. Comparatively, FONAR has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Which has preferable earnings and valuation, FEMY or FONR? FONAR has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than FONAR, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.70M13.91-$14.25M-$0.91-1.02FONAR$103.02M0.87$10.57M$1.2511.60 Does the media favor FEMY or FONR? In the previous week, Femasys and Femasys both had 5 articles in the media. Femasys' average media sentiment score of 0.74 beat FONAR's score of 0.63 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FONAR 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer FEMY or FONR? FONAR received 142 more outperform votes than Femasys when rated by MarketBeat users. Likewise, 74.79% of users gave FONAR an outperform vote while only 73.58% of users gave Femasys an outperform vote. CompanyUnderperformOutperformFemasysOutperform Votes3973.58% Underperform Votes1426.42% FONAROutperform Votes18174.79% Underperform Votes6125.21% Is FEMY or FONR more profitable? FONAR has a net margin of 7.68% compared to Femasys' net margin of -1,435.77%. FONAR's return on equity of 4.94% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,435.77% -141.49% -82.30% FONAR 7.68%4.94%3.70% Do analysts prefer FEMY or FONR? Femasys presently has a consensus target price of $8.67, suggesting a potential upside of 836.94%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than FONAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00FONAR 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryFONAR beats Femasys on 10 of the 17 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.64M$4.37B$5.61B$8.62BDividend YieldN/A42.67%5.28%4.18%P/E Ratio-1.1429.1227.1419.97Price / Sales13.9170.72411.83157.64Price / CashN/A51.0838.2534.64Price / Book1.095.827.064.69Net Income-$14.25M$67.63M$3.23B$248.14M7 Day Performance15.63%0.35%2.67%2.39%1 Month Performance-14.35%15.19%8.82%6.06%1 Year Performance-11.06%17.92%31.44%13.57% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys3.0959 of 5 stars$0.93+8.8%$8.67+836.9%-21.3%$23.64M$1.70M-1.1430News CoverageAnalyst ForecastFONRFONAR1.2937 of 5 stars$14.50flatN/A-4.5%$89.94M$103.02M12.61480News CoveragePositive NewsShort Interest ↑MGRMMonogram Orthopaedics3.0443 of 5 stars$2.41flat$5.40+124.1%+21.7%$86.01M$365.00K-5.1328Positive NewsNSPRInspireMD2.0668 of 5 stars$2.54-0.8%$4.50+77.2%-8.6%$77.81M$7.03M-3.3950SRTSSensus Healthcare2.5043 of 5 stars$4.72-0.8%$11.67+147.2%-10.5%$77.62M$39.49M11.8040Positive NewsINOInovio Pharmaceuticals4.0807 of 5 stars$2.10+5.0%$9.75+364.3%-78.2%$77.02M$283.10K-0.66320Positive NewsMLSSMilestone Scientific2.3097 of 5 stars$0.95+2.4%$1.25+32.3%+22.1%$74.16M$8.61M-13.5030Short Interest ↑VANIVivani Medical2.6382 of 5 stars$1.23-2.4%$4.00+225.2%-27.0%$72.87MN/A-2.7320News CoverageCTCXCarmellN/A$3.30-11.8%N/A+19.9%$68.99M$32.84K0.0014News CoverageGap UpEDAPEdap Tms2.2947 of 5 stars$1.81+1.8%$8.50+369.0%-66.2%$67.77M$62.77M-2.79230Short Interest ↓Analyst RevisionHYPRHyperfine3.395 of 5 stars$0.85+41.1%$1.06+24.7%-7.0%$66.16M$11.73M-1.49190Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies FONAR Alternatives Monogram Orthopaedics Alternatives InspireMD Alternatives Sensus Healthcare Alternatives Inovio Pharmaceuticals Alternatives Milestone Scientific Alternatives Vivani Medical Alternatives Carmell Alternatives Edap Tms Alternatives Hyperfine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.